XML 63 R53.htm IDEA: XBRL DOCUMENT v3.22.1
Geneos Therapeutics, Inc. - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended 7 Months Ended 12 Months Ended
Jun. 01, 2020
Nov. 30, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Feb. 28, 2021
Jun. 30, 2020
Jan. 31, 2020
Jan. 01, 2020
Noncontrolling Interest [Line Items]                    
Payments to acquire additional interest in subsidiaries     $ 1,999,998 $ 0            
Share of net loss in Geneos     $ 2,165,213 434,387            
Geneos Therapeutics, Inc.                    
Noncontrolling Interest [Line Items]                    
Noncontrolling interest, ownership percentage by parent   36.00% 24.00%     61.00% 35.00%     52.00%
Ownership percentage               47.00%    
Geneos Therapeutics, Inc.                    
Noncontrolling Interest [Line Items]                    
Payments to acquire additional interest in subsidiaries   $ 1,400,000       $ 1,200,000        
Stock purchase agreement, commitment of additional investment               $ 800,000 $ 800,000  
Gain on deconsolidation of investment $ 4,100,000                  
Loss from equity method investment, recorded and allocated to investment       (1,500,000)            
Remeasurement of Geneos Series A-1 preferred stock $ 2,400,000                  
Share of net loss in Geneos     $ 434,000              
Investment in equity method investments     0 0            
Geneos Therapeutics, Inc. | Series A One Preferred Stock                    
Noncontrolling Interest [Line Items]                    
Share of net loss in Geneos         $ 819,000          
Geneos Therapeutics, Inc. | Common stock                    
Noncontrolling Interest [Line Items]                    
Investment in equity method investments       0            
Geneos Therapeutics, Inc. | Preferred stock                    
Noncontrolling Interest [Line Items]                    
Share of net loss in Geneos         $ 4,200,000          
Investment in equity method investments     $ (2,000,000) $ 0